GlassScriptPhysician profile
Daynet Hisley
NPI 1871814822
$13,699.92
in general payments reported to CMS, 2019-2025
63 companies · $2,802 in 2025
The $2,802 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,080 · 2020: $1,248 · 2021: $595 · 2022: $2,328 · 2023: $2,488 · 2024: $2,159 · 2025: $2,802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,449.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,798.20 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,001.62 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Ucb, INC. | $793.94 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Amgen INC. | $627.20 | 2019-2023 | Aimovig |
| Pfizer INC. | $620.17 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $518.77 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $386.35 | 2022 | |
| Avanir Pharmaceuticals, INC. | $380.32 | 2019-2022 | |
| Lilly USA, LLC | $364.78 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Biogen, INC. | $335.89 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Allergan, INC. | $329.23 | 2019-2021 | |
| Argenx US, INC. | $315.85 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Celgene Corporation | $314.67 | 2022-2025 | Zeposia |
| Sk Life Science, INC. | $311.03 | 2022-2025 | |
| Csl Behring | $306.07 | 2019-2025 | Hizentra |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $301.05 | 2019-2025 | |
| Lundbeck LLC | $271.48 | 2020-2025 | Vyepti, Rexulti |
| Sunovion Pharmaceuticals INC. | $269.69 | 2019-2022 | |
| Ge Healthcare | $260.85 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $258.96 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $246.55 | 2022-2025 | Ingrezza, Ongentys |
| Otsuka America Pharmaceutical, INC. | $229.94 | 2023-2025 | Rexulti, Nuedexta |
| Alexion Pharmaceuticals, INC. | $208.91 | 2019-2024 | Ultomiris, Soliris |
| Genentech USA, INC. | $204.93 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Genzyme Corporation | $197.86 | 2019-2022 | |
| Neurelis, INC. | $197.81 | 2022-2025 | Valtoco |
| Catalyst Pharmaceuticals, INC. | $193.87 | 2023-2025 | Fycompa |
| Jazz Pharmaceuticals INC. | $187.58 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $176.55 | 2019-2025 | Nuplazid |
| Tanabe Pharma America, INC. | $167.66 | 2023-2025 | Radicava |
| Acorda Therapeutics, INC | $159.18 | 2019-2024 | Ampyra, Inbrija |
| Emd Serono, INC. | $156.02 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $111.31 | 2025 | Ponvory |
| Tg Therapeutics, INC. | $107.41 | 2025 | |
| Mdd US Operations, LLC | $106.60 | 2020-2025 | Gocovri, Gocovri |
| Axsome Therapeutics, INC. | $99.36 | 2025 | Symbravo |
| Novo Nordisk INC | $98.51 | 2024-2025 | Ozempic |
| Livanova USA, INC. | $76.61 | 2020-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Impel Pharmaceuticals INC. | $75.46 | 2023 | Trudhesa |
| Sumitomo Pharma America, INC. | $64.46 | 2023 | Aptiom |
| Takeda Pharmaceuticals U.S.A., INC. | $61.12 | 2023-2024 | Hyqvia |
| Sentynl Therapeutics, INC. | $60.00 | 2022 | |
| Penumbra, INC. | $59.46 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $58.29 | 2020-2023 | Zeposia |
| Janssen Pharmaceuticals, INC | $54.62 | 2021-2023 | Ponvory |
| Boston Scientific Corporation | $46.77 | 2024-2025 | Vercise |
| Alnylam Pharmaceuticals INC. | $46.34 | 2022-2023 | Onpattro |
| Amneal Pharmaceuticals LLC | $45.49 | 2019-2023 | Lyvispah |
| Aucta Pharmaceuticals, INC. | $45.18 | 2025 | Motpoly Xr |
| Upsher-Smith Laboratories LLC | $41.87 | 2020 | |
| Aquestive Therapeutics, INC. | $39.93 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $39.49 | 2022 | |
| Harmony Biosciences LLC | $36.99 | 2020 | |
| Medtronic USA, INC. | $33.59 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $33.14 | 2020 | |
| C2n Diagnostics, LLC | $29.41 | 2025 | Precivityad2 |
| Grifols USA, LLC | $26.11 | 2025 | Gamunex-C |
| Biohaven Pharmaceuticals, INC. | $21.94 | 2021 | |
| Greenwich Biosciences, INC. | $21.88 | 2019 | |
| Merz Pharmaceuticals, LLC | $19.36 | 2025 | Ampyra, Inbrija, Xeomin |
| Astrazeneca Pharmaceuticals LP | $18.51 | 2022 | |
| Nevro Corp. | $15.60 | 2023 | Senza |
| Arbor Pharmaceuticals, INC. | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daynet Hisley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.